Peter Attia's blood tests: the full panel, the five that matter most, and where he goes past the guidelines

Share
Summarize with AI

Peter Attia, the physician behind the 2023 book Outlive, builds his blood work around five tests: apoB, a single Lp(a) test, fasting insulin, hs-CRP (an inflammation marker), and liver and kidney chemistry, with hormones and nutrients added after that. He reads the results for where a patient's arteries and metabolism are heading over the next 30 years. His list, often sold as a longevity blood panel or the Outlive blood tests, has spread across clinics, at-home kits and forums, often with exact targets that cite no book page or episode of his. Below, each test sits beside the guideline that already backs it, and the places where he goes further are marked.

Peter Attia's blood tests, in one table

Attia organises prevention around what he calls the four horsemen: atherosclerotic heart disease, cancer, neurodegenerative disease such as Alzheimer's, and metabolic disease including type 2 diabetes 1. His blood list maps onto them. The guideline column cites the American Heart Association and American College of Cardiology (AHA/ACC), the European cardiology and atherosclerosis societies (ESC/EAS), the American Diabetes Association (ADA) and the international kidney guideline group (KDIGO). A 'risk enhancer' is a result that tips a borderline heart-risk estimate toward treatment.

TestWhat it tells youWhat Attia stressesWhat guidelines say
ApoBHow many particles can lodge in artery wallsHis first lipid number; lower for longerRisk enhancer at 130 mg/dL or more (AHA/ACC); recommended for risk assessment (ESC/EAS)
Lp(a)An inherited particle that adds heart and valve riskTest everyone onceMeasure once in every adult (ESC/EAS 2019, EAS 2022, NLA 2024); AHA/ACC mainly with a family history
Lipid panel (LDL-C, HDL-C, triglycerides)The routine cholesterol readUseful, ranked behind apoBThe base of every heart risk assessment
hs-CRPLow-grade inflammationContext for heart riskRisk enhancer at 2.0 mg/L or more (AHA/ACC)
HbA1c and fasting glucoseAverage and fasting blood sugarLate signals; normal values can hide insulin resistancePrediabetes 5.7 to 6.4%, diabetes 6.5% or more (ADA)
Fasting insulin, or an oral glucose tolerance test (OGTT) with insulinHow hard the pancreas works to keep glucose normalAn earlier warning than glucoseNo agreed cutoff; not part of routine screening
Uric acid, triglyceride/HDL ratioSide signals of metabolic strainRead alongside insulinUric acid is checked mainly for gout and kidney stones
ALT, AST (liver enzymes), GGTLiver cell stress, including fatty liverFatty liver can sit inside a 'normal' ALTALT and AST come in the standard metabolic panel; GGT is an add-on
Creatinine-based eGFR, cystatin CHow well the kidneys filterCreatinine misreads muscular peopleKDIGO 2024: add cystatin C when accuracy matters
Testosterone with SHBG (its binding protein), thyroid panel, DHEA-SHormone statusTracked over timeOrdered when symptoms point to them
Vitamin D, ferritin, RBC magnesium, omega-3 indexNutrient statusTracked over timeEndocrine Society 2024 suggests against routine vitamin D testing in healthy adults
APOE genotypeInherited Alzheimer's riskCentral to his brain-health chapterNo guideline recommends it as a population screen

Exact Attia targets for TSH, ALT or fasting insulin that circulate online usually cite no book page or episode. The positions in this table come from Outlive 1, and every number is a guideline value you can check against its source.

Who he is, and why people copy his panel

Attia is a physician (Stanford medical school, surgical training at Johns Hopkins) who runs a longevity practice, hosts the podcast The Drive and wrote Outlive: The Science and Art of Longevity with Bill Gifford, published by Harmony Books in March 2023 1. His frame is what he calls Medicine 3.0: act on risk decades before a disease can be diagnosed, instead of treating it once it arrives. That is why his panel goes deeper than a routine physical. The longevity hub collects the wider topic.

If you only get five: the short list

  1. ApoB: the particle count behind heart disease, and Attia's first lipid number.
  2. Lp(a), once: inherited, missing from a standard lipid panel, and close to fixed for life.
  3. Fasting insulin beside fasting glucose and HbA1c: the early read on insulin resistance. An OGTT (a sugar drink with blood drawn over two hours) with insulin goes further.
  4. hs-CRP (high-sensitivity C-reactive protein): a low-grade inflammation signal that the AHA/ACC guideline counts as a risk enhancer at 2.0 mg/L or more 2.
  5. A comprehensive metabolic panel (CMP, the routine chemistry panel with liver and kidney tests) plus cystatin C.

A routine US physical usually includes the lipid panel and the CMP, and often HbA1c. ApoB, Lp(a), fasting insulin, hs-CRP and cystatin C are the ones you normally have to ask for by name. Our guide to what blood tests to get covers the wider list by age and sex.

ApoB: the number he cares about most

Every particle that can push cholesterol into an artery wall (LDL and its close relatives VLDL, IDL and Lp(a)) carries exactly one apolipoprotein B molecule, so an apoB result is a particle count. LDL cholesterol measures how much cholesterol those particles carry. When the two disagree, risk tends to follow apoB. A 2022 UK Biobank analysis by Marston and colleagues found that heart attack risk tracked the number of apoB particles, whether they were LDL or triglyceride-rich particles 7. The apoB vs LDL comparison works through when the two numbers part ways.

Interactive

Do your apoB and LDL agree?

Enter both numbers to see whether your particle count and your cholesterol tell the same story. Nothing leaves your browser.

Enter both your LDL-C and apoB to compare them.
Have your own numbers?Have your results? Read them free.Drop in your lab report and see every marker explained in plain words, placed on the body, against your lab's range. It's read on your device: nothing is uploaded and nothing is kept.Read my results

Attia's view, set out in Outlive, is that apoB damage builds up over a lifetime, so he wants apoB as low as can be reached safely and as early as possible 1. He gives no single target for everyone. His reference point is the very low apoB of children, far below any adult guideline goal. Guidelines step in later and aim less low. The AHA/ACC 2018 guideline treats an apoB of 130 mg/dL or more as a risk-enhancing factor 2. The ESC/EAS 2019 guideline recommends apoB for risk assessment, especially in people with high triglycerides, diabetes, obesity or very low LDL-C, and sets goals by risk level 3.

Risk level (ESC/EAS 2019)ApoB goalLDL-C goal
Very highBelow 65 mg/dLBelow 55 mg/dL and at least a 50% cut
HighBelow 80 mg/dLBelow 70 mg/dL and at least a 50% cut
ModerateBelow 100 mg/dLBelow 100 mg/dL

If your apoB is 130 mg/dL or more, or above the goal for your risk level, take it to a clinician with your family history and ask what your 10-year heart risk is and whether treatment makes sense. Lowering apoB usually starts with food (less saturated fat, more fibre) and, when a clinician judges it worthwhile, moves to medicines such as statins, ezetimibe or PCSK9 inhibitors.

If apoB is missing from your report, non-HDL cholesterol (total cholesterol minus HDL) is a free stand-in from the lipid panel you already have. The cholesterol ratio calculator does the arithmetic, and how to read your lipid panel covers the rest of the report.

Lp(a): test it once, then plan around it

Lipoprotein(a), written Lp(a), is an LDL-like particle with an extra protein attached. The LPA gene sets most of its level, so diet and exercise barely move it, and about 1 in 5 people carry enough Lp(a) to raise heart attack and aortic valve risk 4. Statins tend to nudge Lp(a) up slightly on average 8. That small rise is no reason to stop a statin, because the apoB it lowers matters more. A standard lipid panel never reports Lp(a), so Attia argues that everyone should have it measured once 1, and the European guideline agrees.

Lp(a) measurement should be considered at least once in each adult person's lifetime to identify those with very high inherited Lp(a) levels >180 mg/dL (>430 nmol/L) who may have a lifetime risk of ASCVD equivalent to the risk associated with heterozygous familial hypercholesterolaemia.2019 ESC/EAS Guidelines for the management of dyslipidaemias 3

In plain words, one Lp(a) test can find people whose inherited heart risk matches that of familial hypercholesterolemia, a genetic cholesterol disorder. The EAS 2022 consensus 4 and the National Lipid Association's 2024 update 9 also say to measure Lp(a) at least once in every adult. The US AHA/ACC guideline is narrower and suggests Lp(a) mainly for people with a family history of early heart disease 2.

Labs report Lp(a) in nmol/L, a particle count, or in mg/dL, a mass. No exact factor converts one to the other, so compare a result only against cutoffs in its own unit.

Interactive

Read your Lp(a), in the right unit

mg/dL and nmol/L are not the same scale. Enter your value with its unit. Nothing leaves your browser.

Unit
Enter your Lp(a) value and choose its unit to see where it sits.
Have your own numbers?Have your results? Read them free.Drop in your lab report and see every marker explained in plain words, placed on the body, against your lab's range. It's read on your device: nothing is uploaded and nothing is kept.Read my results

An example Lp(a) result against the EAS cutoffsnmol/L

140 nmol/Labove the rule-in line · roughly 55 to 60 mg/dL; the conversion is approximate
Rule-out0–75Grey zone75–125Raises risk125–250
An Lp(a) of 140 nmol/L adds to heart and valve risk for life. A clear result like this rarely needs repeating. It is a reason to ask a clinician how hard to lower apoB and whether close relatives should be tested.
Illustrative example value. Cutoffs from the EAS 2022 consensus statement 4; the AHA/ACC 2018 guideline uses 125 nmol/L (50 mg/dL) as its risk-enhancer line 2.

A high Lp(a) changes the plan around it. The EAS 2022 consensus advises treating other risk factors, apoB included, more intensively when Lp(a) is high, and testing first-degree relatives because the trait is inherited 4. Drugs built to lower Lp(a) directly, such as pelacarsen and olpasiran, have gone into large outcome trials to see whether they prevent heart attacks and strokes. If yours is high, ask your clinician where those drugs stand and whether one, or a trial, suits you. For now, the main lever a clinician can use is lowering apoB.

Metabolic health: why HbA1c is not enough for him

The ADA defines prediabetes as an HbA1c of 5.7 to 6.4% and diabetes as 6.5% or more 5. Attia's objection is timing. HbA1c and fasting glucose can stay normal for years while the pancreas pours out extra insulin to hold them there 1. So he treats the ADA lines as late signals and measures insulin itself, either fasting or across an OGTT with insulin drawn at each time point. He has also described wearing a continuous glucose monitor (CGM) to see how meals land 1. Exact Attia HbA1c targets that circulate online, such as below 5.5%, usually come without a source.

How insulin resistance shows up on a blood panel, in order

1
Cells respond less to insulin
Muscle and liver need more insulin to clear the same glucose, often alongside visceral fat and low activity.
2
Insulin rises while glucose stays normal
The pancreas compensates. Fasting insulin and the OGTT insulin curve climb while HbA1c still reads normal.
3
Glucose after meals creeps up
Compensation starts to slip. The two-hour OGTT glucose usually rises before fasting glucose does.
4
Fasting glucose and HbA1c cross the lines
HbA1c reaches 5.7%, the ADA prediabetes line, and later 6.5%, the diabetes line.
The sequence follows Attia's account of insulin resistance in Outlive 1; the cutoffs are the ADA's 5.

HOMA-IR turns a fasting insulin and a fasting glucose into one estimate of insulin resistance: insulin (µU/mL) times glucose (mg/dL), divided by 405 10. Insulin assays differ between labs and there is no universal HOMA-IR cutoff, so read it as a trend in your own numbers.

CalculatorHOMA-IR calculatorHolding a fasting insulin and a fasting glucose from the same draw? This turns them into a HOMA-IR estimate.Work it out

The triglyceride-to-HDL ratio and uric acid, which doctors usually check for gout, are cheaper side signals of the same strain. The two-hour OGTT glucose catches after-meal problems a fasting test misses. The A1C vs fasting glucose comparison explains what each standard test leaves out, and insulin resistance covers the condition itself.

Inflammation, liver and kidneys

hs-CRP reads low-grade inflammation in mg/L, and the AHA/ACC guideline counts 2.0 mg/L or more as a heart risk enhancer 2. hs-CRP vs CRP explains why the two tests are read differently.

On the liver, Attia's concern is fatty liver hiding behind a 'normal' ALT 1. Many labs set the ALT upper limit from populations that include people with undiagnosed fatty liver, so an ALT near the top of the range can still reflect fat in the liver. GGT (gamma-glutamyl transferase) adds a read on alcohol and bile-duct stress, and the AST/ALT ratio helps separate patterns. See liver enzymes explained and fatty liver.

For the kidneys, the usual eGFR (estimated glomerular filtration rate, how much blood the kidneys filter each minute) is calculated from creatinine, which comes from muscle. A muscular person can look as if their kidneys filter less than they do. The KDIGO 2024 kidney guideline supports adding cystatin C, which muscle mass does not drive, when a more accurate eGFR matters 11. Cystatin C vs creatinine shows when the two disagree. Homocysteine appears on many longevity panels too, and a high result often traces back to low B12 or folate.

Hormones and nutrients: where the evidence is softest

Attia also tracks testosterone with SHBG (the binding protein that decides how much testosterone is free to act), a thyroid panel (TSH, free T4, free T3), DHEA-S (an adrenal hormone), vitamin D, ferritin, magnesium and the omega-3 index. These tests are worth knowing, and they are where copying someone else's target matters least. The 'optimal' ranges that circulate for them come mostly from observational studies, where people with a given level did better, which leaves open whether the level caused the benefit.

TestWhat the 'optimal' range rests onWhere guidelines stand
Vitamin D (25-OH D)Observational links; the VITAL trial found no cancer or heart benefit from supplementsEndocrine Society 2024 suggests against routine testing in healthy adults and sets no target level
Omega-3 index8% or more linked with the lowest coronary death rates in observational dataNo guideline target, and no trial has tested raising the index to 8%
RBC magnesiumPromoted by longevity clinics as a better read of body stores than serum magnesiumNo guideline has adopted it
FerritinLow means thin iron stores; high can mean inflammation, liver disease or iron overloadRead with the rest of the iron tests; both ends matter

The omega-3 index measures EPA and DHA as a share of the fats in red cell membranes, and the 8% figure comes from observational data published in 2004 13. The omega-3 page grades the fish oil trials, and RBC magnesium has its own page. A low ferritin is worth raising with a clinician, and a high one can point to hemochromatosis, an inherited iron overload.

For the hormone tests, start with the male hormone panel guide, the free testosterone calculator and how to read your thyroid panel.

The tests that are not blood tests

Attia weighs several measures that need no blood draw as heavily as anything on the panel 1.

  • VO2 max, the most oxygen your body can use during hard exercise. Attia treats cardiorespiratory fitness as one of the strongest predictors of how long people live 1. The VO2 max calculator gives an estimate without a lab.
  • A DEXA scan, which measures muscle, visceral fat and bone density in one low-dose scan. Without a scan, the lean body mass and body fat calculators give a rougher read.
  • Coronary imaging. A coronary calcium score shows hardened plaque. Attia has written that he favours CT angiography for some patients because it also shows soft plaque that a calcium score of zero can miss 1.
  • Cancer screening. He argues for starting colonoscopy earlier than 45, the age at which the US Preventive Services Task Force (USPSTF) starts routine colorectal screening 1 14. For PSA, the USPSTF advises men aged 55 to 69 to decide individually and recommends against screening at 70 and older 15. Multi-cancer blood tests are covered in the Galleri test.

One genetic test sits on his list as well. APOE genotype shows inherited Alzheimer's risk and is central to his brain-health chapter 1, but no guideline recommends it as a screen. A result cannot be unlearned, and for people without memory symptoms no treatment depends on it (it matters mainly when someone with Alzheimer's is weighing an anti-amyloid drug, whose brain-swelling risk is higher in APOE4 carriers), so if you are curious, talk it through with a clinician or genetic counsellor first.

How often to retest

A workable rhythm has four parts: one full baseline, Lp(a) once, most other tests about once a year, and a recheck 4 to 12 weeks after a change in diet or medicine to see whether it worked. The 4-to-12-week window matches the AHA/ACC guideline's advice for checking lipids after a statin is started or changed 2. Repeat Lp(a) only if the first result was borderline or the lab's method was questionable.

The split follows biology. Genes set Lp(a), so one good measurement does the job. ApoB, insulin, hs-CRP and liver enzymes move with diet, weight and medicine, so the second and third readings tell you more than the first. Three readings from the same lab with the same preparation make a trend. Keep fasting consistent, skip hard exercise the day before, and draw at a similar time of day. See why trends beat single readings, how to prepare for a blood test and exercise before a blood test.

How to get these tests in the US

A regular doctor can order every blood test on this list. If you want them, ask by name and tell your doctor about anything that applies to you, such as a family history of early heart disease, high triglycerides, an HbA1c in the prediabetes range, or a muscular build that skews creatinine. Insurance plans differ in what they cover for apoB, Lp(a) and cystatin C. Direct-to-consumer labs also sell most of these tests at cash prices.

To compare options, see the cheapest blood tests, the best at-home blood tests and whether at-home tests are accurate. Whoop Advanced Labs is one consumer bundle built around many of these markers.

Already have results? Read them line by line

If you already hold a lipid panel and a CMP, you have roughly half of the tests on Attia's list, and those results are worth reading closely before adding more. A high apoB or Lp(a) is a result to take to a clinician. It is no reason to start a supplement or a diet protocol on your own.

Free, no accountRead your blood testHave a lipid panel or a CMP? See where each value sits.Read my results
The distinctions
  1. 01
    His tests are mostly mainstream, his targets are his own

    A cardiologist following the 2018 AHA/ACC or 2019 ESC/EAS cholesterol guideline can already order apoB and hs-CRP, and European and US lipid societies advise testing Lp(a) once in every adult. Attia aims lower and starts earlier, and no trial has tested driving apoB that low from early adulthood in healthy people. The tests themselves are widely available; the targets are a conversation to have with your clinician.

Citations
  1. Attia P, Gifford B. Outlive: The Science and Art of Longevity. Harmony Books, 2023.
  2. Grundy SM et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. Circulation 2019;139:e1082-e1143.
  3. Mach F et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. European Heart Journal 2020;41(1):111-188.
  4. Kronenberg F et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. European Heart Journal 2022;43(39):3925-3946.
  5. American Diabetes Association Professional Practice Committee. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes 2025. Diabetes Care 2025;48(Suppl 1):S27-S49.
  6. Demay MB et al. Vitamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism 2024;109(8):1907-1947.
  7. Marston NA et al. Association of Apolipoprotein B-Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis. JAMA Cardiology 2022;7(3):250-256.
  8. Tsimikas S et al. Statin therapy increases lipoprotein(a) levels. European Heart Journal 2020;41(24):2275-2284.
  9. Koschinsky ML et al. A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice. Journal of Clinical Lipidology 2024;18(3):e308-e319.
  10. Matthews DR et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28(7):412-419.
  11. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney International 2024;105(4S):S117-S314.
  12. Manson JE et al. Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease (VITAL). New England Journal of Medicine 2019;380(1):33-44.
  13. Harris WS, von Schacky C. The Omega-3 Index: a new risk factor for death from coronary heart disease? Preventive Medicine 2004;39(1):212-220.
  14. US Preventive Services Task Force. Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. JAMA 2021;325(19):1965-1977.
  15. US Preventive Services Task Force. Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement. JAMA 2018;319(18):1901-1913.

Educational context only, not medical advice or a diagnosis. Always discuss your results with a clinician.